NRSN NeuroSense Therapeutics Ltd.

2.35
-0.04  -2%
Previous Close 2.39
Open 2.31
52 Week Low 2.32
52 Week High 4.6998
Market Cap $25,717,305
Shares 10,943,534
Float 7,776,434
Enterprise Value $24,723,304
Volume 200,145
Av. Daily Volume 249,958
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Prime C
Amyotrophic Lateral Sclerosis
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa clinical trial results have been accepted at the 16th International Conference on Alzheimer's & Parkinson's (AD/PD) to be held in Barcelona in March 2022. AD/PD is an international medical and scientific conference for Alzheimer's & Parkinson's disease and other neurological diseases. 

    During the fourth quarter of 2021, NeuroSense presented clinical and pre-clinical data at three prestigious conferences: the Annual ALS ONE Research Symposium; the ALS/MND Symposium 2021; and the Israeli Neurological Association Annual Meeting.

    The presentations also focused on key clinical findings from NeuroSense's phase IIa clinical study which showed promising clinical outcomes together with significant changes in ALS-related biomarkers.

    "We are excited and honored to be presenting our work at these leading conferences, and we thank the organizers for providing us the opportunity to be on the podium. Our findings have provided valuable insights into the pathologies of ALS and the mechanism of action for PrimeC's, the lead product in our pipeline," noted Dr. Shiran Zimri, PhD., Head of the Scientific Programs at NeuroSense. "We are hopeful that participation in these leading conferences will pave the way to further collaborations and advancement of our product portfolio."

    Alon Ben-Noon, NeuroSense's CEO added: "The positive reception that NeuroSense has received from the scientific community helps to emphasize the novelty and importance of our PrimeC clinical trial findings for ALS. With the recent completion of our initial public offering and listing on NASDAQ, we are well financed to work closely with leading clinicians and patient advocacy groups and to advance our ALS clinical program towards initiation of our Phase IIb study."

    About NeuroSense

    NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

    Forward-Looking Statements

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding participation in conferences; the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-therapeutics-ltd-announces-the-presentation-of-phase-iia-study-results-at-four-international-conferences-301453632.html

    SOURCE NeuroSense

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO. The new directors will join the current directors, Mark Leuchtenberger, Chairman of the Board, and Alon Ben-Noon, the CEO and founder.

    The new directors bring a diverse set of experiences in healthcare and the biotechnology industry that will be instrumental for guiding NeuroSense through the development and commercialization of its product portfolio. Joining the NeuroSense board are: 

    • Yael German, a former Israeli Member of Knesset and former Minister of Health;
    • Caren Deardorf, currently Chief Commercial Officer at Magenta Therapeutics, who previously led multiple global launches across rare disease and neurology at Biogen Inc.;
    • Christine Pellizzari, currently Chief Legal Officer at Science 37 and a veteran of several rare disease focused biotech companies in similar roles; and
    • Cary Claiborne, currently Chief Operating Officer and board member at Adial Pharmaceuticals and the founder and CEO of Prosperity Capital Management, LLC. 

    Ms. Pellizzari will chair the Compensation Committee and Mr. Claiborne, with extensive experience as the CFO of several biotech companies, will chair the Audit Committee.

    As the company previously announced, since October 1, 2021 Mark Leuchtenberg serves as the Chairman of the Board . Mr. Leuchtenberger has over 25 years of experience as a senior executive in the biopharmaceutical industry where he has led companies through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits and served as a President, Chief Executive Officer and a board member at several publicly traded companies.

    In addition to the new board appointments, the company is pleased to announce that Dr. Ferenc Tracik, a neurologist with significant scientific and management experience in developing neurodegenerative therapies with companies such as Biogen, Novartis and Orphazyme, has joined the company and will serve as Chief Medical Officer.

    "I am very excited to join NeuroSense and to help advance the mission of bringing novel therapies to patients with Amyotrophic Lateral Sclerosis and other neurodegenerative diseases with a high unmet medical need. I am looking forward to being part of a highly motivated and experienced team and applying my experience in clinical research, medical affairs, commercial and clinical practice to improve the treatment options for patients suffering from these devastating diseases," said Dr. Tracik.

    "These important additions to the company's Board of Directors and its senior management team reflect the growth trajectory that the company is charting following our initial public offering. We are committed to achieving both our corporate and scientific milestones on behalf of our shareholders and patients in need of our novel therapies," said Alon Ben-Noon, NeuroSense's CEO.

    Mark Leuchtenberger, Chairman of the Board, added, "These commitments and anticipated contributions to NeuroSense by Dr. Tracik and these highly accomplished Board members provide the latest validation for our drug candidates and our strategy to develop effective therapeutic options for ALS and other patients with debilitating and often fatal diseases.  We have assembled an extremely strong team and we look forward to working together to address and surmount the challenges ahead of us."

    About NeuroSense

    NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited and often ineffective therapeutic options currently available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

    Forward-Looking Statements

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

    Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-therapeutics-ltd-expands-board-of-directors-and-adds-chief-medical-officer-to-leadership-team-301448997.html

    SOURCE NeuroSense

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd., (NASDAQ:NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease, today announced the closing of its previously announced initial public offering on the Nasdaq Capital Market of 2,000,000 units, each consisting of one ordinary share and a warrant representing the right to purchase one ordinary share with an exercise price of $6.00 per share, at an initial public offering price of $6.00 per unit. In addition, NeuroSense has granted the underwriter a 45-day option to purchase up to 300,000 additional…

    CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd., (NASDAQ:NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease, today announced the closing of its previously announced initial public offering on the Nasdaq Capital Market of 2,000,000 units, each consisting of one ordinary share and a warrant representing the right to purchase one ordinary share with an exercise price of $6.00 per share, at an initial public offering price of $6.00 per unit. In addition, NeuroSense has granted the underwriter a 45-day option to purchase up to 300,000 additional ordinary shares and/or 300,000 additional warrants at the initial public offering price, less underwriting discounts and commissions. The underwriter partially exercised its option and purchased an additional 300,000 warrants, each representing the right to purchase one ordinary share. NeuroSense's ordinary shares and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbols "NRSN" and "NRSNW," respectively. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $12 million, inclusive of the underwriter's option.

    NeuroSense Therapeutics Logo

    Maxim Group LLC acted as the sole book-running manager for the offering.

    NeuroSense received net proceeds from this offering of approximately $9.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by NeuroSense.  NeuroSense intends to use the net proceeds from this offering to advance the clinical development of its lead product candidate, PrimeC, for the treatment of ALS through the completion of a planned Phase IIb trial and the preparation for the initiation of a Phase III clinical trial, for preclinical research and development in support of potential investigational new drug applications for its product candidates targeting Alzheimer's and Parkinson's, and for working capital and general corporate purposes.

    Alon Ben-Noon, NeuroSense's CEO said: "We are thankful to all the investors that participated in the IPO and of course all of those who supported NeuroSense from the start. Many of our investors are also ALS patients and their family members and we are proud of that. The completion of this IPO is a significant milestone in our ongoing effort to bring effective treatments to patients suffering from neurodegenerative diseases."

    Mark Leuchtenberger, Board Chairman of NeuroSense, added, "With this successful IPO the company enters a new era in its mission to improve the lives of ALS and other patients through the development of new treatment options.  Many of us at NeuroSense have lost friends and family to these diseases, and we have made a promise to work tirelessly towards this goal.  With these funds we are now implementing plans with the potential to deliver on that promise."

    A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission (the "SEC") and declared effective on December 8, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the initial public offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov.  Alternatively, electronic copies of the final prospectus may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, at (212) 895-3745.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

    About NeuroSense Therapeutics

    NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

    Forward-Looking Statements

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the expected use of proceeds. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

    Cision View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-closing-of-initial-public-offering-on-nasdaq-capital-market-301443478.html

    SOURCE NeuroSense

    View Full Article Hide Full Article
View All NeuroSense Therapeutics Ltd. News